Integrating molecular diagnostics into anticancer drug discovery

被引：0

作者：

István Peták

Richárd Schwab

László Őrfi

László Kopper

György Kéri

机构：

[1] István Peták is at KPS Medical Biotechnology and Healthcare Services Ltd,and the Ist Department of Pathology and Experimental Cancer Research

[2] 5 Ribary,and the Department of Pharmaceutical Chemistry

[3] 1022 Budapest,László Kopper is at the Ist Department of Pathology and Experimental Cancer Research

[4] Hungary,Department of Medical Chemistry and Pathobiochemistry

[5] Semmelweis University,undefined

[6] 26 Üllői út,undefined

[7] 1085 Budapest,undefined

[8] Hungary.,undefined

[9] Richárd Schwab is at KPS Medical Biotechnology and Healthcare Services Ltd,undefined

[10] 5 Ribary,undefined

[11] 1022 Budapest,undefined

[12] Hungary.,undefined

[13] László Őrfi is at Vichem Chemie Research Ltd,undefined

[14] Budapest,undefined

[15] Hungary,undefined

[16] Semmelweis University,undefined

[17] Högyes E. u. 9.,undefined

[18] 1092 Budapest,undefined

[19] Hungary.,undefined

[20] Semmelweis University,undefined

[21] 26 Üllői út,undefined

[22] 1085 Budapest,undefined

[23] Hungary.,undefined

[24] György Kéri is at Vichem Chemie Research Ltd,undefined

[25] Budapest,undefined

[26] Hungary,undefined

[27] and the Pathobiochemistry Research Group of the Hungarian Academy of Sciences,undefined

[28] Semmelweis University,undefined

[29] Budapest,undefined

[30] H-1085,undefined

[31] Hungary.,undefined

来源：

Nature Reviews Drug Discovery | 2010年 / 9卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Efforts to repeat the success of pioneering molecularly targeted cancer drugs, such as trastuzumab, for particular patient populations have been hampered by factors such as a lack of correlation between the molecular markers used to select patients for treatment and the drug response. This article highlights lessons learned from the development of drugs targeting members of the epidermal growth factor receptor family, and discusses strategies to decrease the risk of failure in clinical trials by more effectively integrating molecular diagnostics into anticancer drug discovery and development.

引用

页码：523 / 535

页数：12

共 50 条

[21] SURAMIN - THE DISCOVERY OF AN OLD ANTICANCER DRUG
ZANIBONI, A
MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1990, 7 (04): : 287 - 290
[22] Current targets for anticancer drug discovery
Nam, NH
Parang, K
CURRENT DRUG TARGETS, 2003, 4 (02) : 159 - 179
[23] Enzymatic Targets in the Anticancer Drug Discovery
Scotti, Luciana
Scotti, Marcus T.
CURRENT PROTEIN & PEPTIDE SCIENCE, 2024, 25 (01) : 3 - 3
[24] Phenotypic strategies for anticancer drug discovery
Garner, Steven M.
Croff, Alyssa M.
Lipner, Justin H.
O'Mahony, Alison
Velichko, Sharlene
King, Alastair J.
Parry, Jesse J.
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[25] Anticancer drug discovery: Role of pharmacogenomics
Ray, Abhijit
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2006, 27 (03) : 12 - 19
[26] Role of plants in anticancer drug discovery
Khazir, Jabeena
Mir, Bilal Ahmad
Pilcher, Lynne
Riley, Darren L.
PHYTOCHEMISTRY LETTERS, 2014, 7 : 173 - 181
[27] Role of Docking in Anticancer Drug Discovery
Alavi, Asif
Sharma, Vikas
LETTERS IN DRUG DESIGN & DISCOVERY, 2023, 20 (10) : 1490 - 1511
[28] Drug discovery in academia: Anticancer research
Jung, Michael
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
[29] Thiazole in the targeted anticancer drug discovery
Ayati, Adileh
Emami, Saeed
Moghimi, Setareh
Foroumadi, Alireza
FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1929 - 1952
[30] A Novel Strategy for the Discovery of Drug Targets: Integrating Clinical Evidence with Molecular Studies
Kaneko, Shuji
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (02) : 345 - 349

← 1 2 3 4 5 →